Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

The Processing of Xenografts Will Result in Different Clinical Responses.

Block MS.

J Oral Maxillofac Surg. 2018 Oct 12. pii: S0278-2391(18)31168-6. doi: 10.1016/j.joms.2018.10.004. [Epub ahead of print] Review.

PMID:
30414391
2.

The Crestal Window Approach for Sinus Floor Grafting With Delayed Implant Placement: A Preliminary Report.

Block MS.

J Oral Maxillofac Surg. 2018 Jul 9. pii: S0278-2391(18)30755-9. doi: 10.1016/j.joms.2018.06.171. [Epub ahead of print]

PMID:
30075137
3.

Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients.

Wang L, Felts SJ, Van Keulen VP, Scheid AD, Block MS, Markovic SN, Pease LR, Zhang Y.

Cancer Res. 2018 Aug 1;78(15):4411-4423. doi: 10.1158/0008-5472.CAN-18-0529. Epub 2018 Jun 12.

PMID:
29895674
4.

Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.

Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, Padley D, Gustafson MP, Shreeder B, Puglisi-Knutson D, Visscher DW, Mangskau TK, Wilson G, Knutson KL.

Clin Cancer Res. 2018 Jul 1;24(13):3014-3025. doi: 10.1158/1078-0432.CCR-17-2499. Epub 2018 Mar 15.

PMID:
29545464
5.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL.

Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.

6.

Neoadjuvant systemic therapy for regionally advanced melanoma.

Jakub JW, Racz JM, Hieken TJ, Gonzalez AB, Kottschade LA, Markovic SN, Yan Y, Block MS.

J Surg Oncol. 2018 May;117(6):1164-1169. doi: 10.1002/jso.24939. Epub 2017 Dec 11.

PMID:
29228467
7.

Dental Implants: The Last 100 Years.

Block MS.

J Oral Maxillofac Surg. 2018 Jan;76(1):11-26. doi: 10.1016/j.joms.2017.08.045. Epub 2017 Oct 13.

PMID:
29079267
8.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.

JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.

9.

IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.

Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, Knutson KL.

Cancer Res. 2017 Dec 1;77(23):6667-6678. doi: 10.1158/0008-5472.CAN-17-0740. Epub 2017 Oct 9.

PMID:
28993412
10.

Closed Approach for Horizontal Augmentation of the Maxilla.

Block MS.

J Oral Maxillofac Surg. 2018 Mar;76(3):521-527. doi: 10.1016/j.joms.2017.08.011. Epub 2017 Aug 12.

PMID:
28886354
11.

Inflammatory and Nutritional Serum Markers as Predictors of Peri-operative Morbidity and Survival in Ovarian Cancer.

Kumar A, Torres ML, Cliby WA, Kalli KR, Bogani G, Aletti G, Nitschmann CC, Multinu F, Weaver AL, Block MS, Mariani A.

Anticancer Res. 2017 Jul;37(7):3673-3677.

PMID:
28668859
12.

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.

Colon-Otero G, Weroha SJ, Foster NR, Haluska P, Hou X, Wahner-Hendrickson AE, Jatoi A, Block MS, Dinh TA, Robertson MW, Copland JA.

Gynecol Oncol. 2017 Jul;146(1):64-68. doi: 10.1016/j.ygyno.2017.04.020. Epub 2017 Apr 28.

PMID:
28461031
13.

Facial diplegia after pembrolizumab treatment.

Yost MD, Chou CZ, Botha H, Block MS, Liewluck T.

Muscle Nerve. 2017 Sep;56(3):E20-E21. doi: 10.1002/mus.25663. Epub 2017 May 6. No abstract available.

PMID:
28398689
14.

Implant Placement Is More Accurate Using Dynamic Navigation.

Block MS, Emery RW, Cullum DR, Sheikh A.

J Oral Maxillofac Surg. 2017 Jul;75(7):1377-1386. doi: 10.1016/j.joms.2017.02.026. Epub 2017 Mar 14.

PMID:
28384461
15.

Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.

Leon-Ferre RA, Kottschade LA, Block MS, McWilliams RR, Dronca RS, Creagan ET, Allred JB, Lowe VJ, Markovic SN.

Melanoma Res. 2017 Aug;27(4):335-341. doi: 10.1097/CMR.0000000000000344.

PMID:
28296712
16.

A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome.

Jatoi A, Grudem ME, Dockter TJ, Block MS, Villasboas JC, Tan A, Deering E, Kasi PM, Mansfield AS, Botero JP, Okuno SH, Smith DR, Fields AP.

Support Care Cancer. 2017 Mar;25(3):833-838. doi: 10.1007/s00520-016-3467-9. Epub 2016 Nov 12.

17.

Improvements in the Crestal Osteotome Approach Have Decreased the Need for the Lateral Window Approach to Augment the Maxilla.

Block MS.

J Oral Maxillofac Surg. 2016 Nov;74(11):2169-2181. doi: 10.1016/j.joms.2016.06.008. Epub 2016 Jun 14.

PMID:
27380546
18.

Implant Placement Accuracy Using Dynamic Navigation.

Block MS, Emery RW, Lank K, Ryan J.

Int J Oral Maxillofac Implants. 2017 Jan/Feb;32(1):92-99. doi: 10.11607/jomi.5004. Epub 2016 Sep 19.

PMID:
27643585
19.

The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.

Li Z, Block MS, Vierkant RA, Fogarty ZC, Winham SJ, Visscher DW, Kalli KR, Wang C, Goode EL.

Tumour Biol. 2016 Oct;37(10):13279-13286. doi: 10.1007/s13277-016-5163-2. Epub 2016 Jul 26.

20.

Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer.

Wang C, Winterhoff BJ, Kalli KR, Block MS, Armasu SM, Larson MC, Chen HW, Keeney GL, Hartmann LC, Shridhar V, Konecny GE, Goode EL, Fridley BL.

Br J Cancer. 2016 Jun 14;114(12):1412-20. doi: 10.1038/bjc.2016.124. Epub 2016 Jun 2.

21.

T cell Bim levels reflect responses to anti-PD-1 cancer therapy.

Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Mansfield AS, Park SS, Markovic SN, Dong H.

JCI Insight. 2016 May 5;1(6). pii: e86014.

22.

Static and Dynamic Navigation for Dental Implant Placement.

Block MS.

J Oral Maxillofac Surg. 2016 Feb;74(2):231-3. No abstract available.

PMID:
27170955
23.

Accuracy Using Static or Dynamic Navigation.

Block MS.

J Oral Maxillofac Surg. 2016 Jan;74(1):2-3. No abstract available.

PMID:
27110617
24.

The use of pembrolizumab for the treatment of metastatic uveal melanoma.

Kottschade LA, McWilliams RR, Markovic SN, Block MS, Villasboas Bisneto J, Pham AQ, Esplin BL, Dronca RS.

Melanoma Res. 2016 Jun;26(3):300-3. doi: 10.1097/CMR.0000000000000242.

PMID:
26848796
25.

Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic Melanoma.

White ML, Atwell TD, Kurup AN, Schmit GD, Carter RE, Geske JR, Kottschade LA, Pulido JS, Block MS, Jakub JW, Callstrom MR, Markovic SN.

Mayo Clin Proc. 2016 Mar;91(3):288-96. doi: 10.1016/j.mayocp.2015.10.025. Epub 2016 Jan 28. Review.

PMID:
26827235
26.

Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of Ovarian Cancer.

Jatoi A, Vierkant RA, Hawthorne KM, Block MS, Ramus SJ, Larson NB, Fridley BL, Goode EL.

Oncology. 2016;90(2):59-68. doi: 10.1159/000442710. Epub 2016 Jan 19.

27.

Treatment of HIV/AIDS associated cancers with immunotherapy targeting PD-1/PD-L1 instead of chemotherapy.

Kasi PM, Block MS, Ansell SM.

Med Hypotheses. 2016 Jan;86:129-31. doi: 10.1016/j.mehy.2015.11.003. Epub 2015 Nov 5.

PMID:
26559886
28.

Static or Dynamic Navigation for Implant Placement-Choosing the Method of Guidance.

Block MS, Emery RW.

J Oral Maxillofac Surg. 2016 Feb;74(2):269-77. doi: 10.1016/j.joms.2015.09.022. Epub 2015 Sep 30. Review.

PMID:
26452429
29.

Gene expression patterns in CD4+ peripheral blood cells in healthy subjects and stage IV melanoma patients.

Felts SJ, Van Keulen VP, Scheid AD, Allen KS, Bradshaw RK, Jen J, Peikert T, Middha S, Zhang Y, Block MS, Markovic SN, Pease LR.

Cancer Immunol Immunother. 2015 Nov;64(11):1437-47. doi: 10.1007/s00262-015-1745-x. Epub 2015 Aug 6.

30.

Ureteral obstruction in cancer patients: a qualitative study.

Kumar A, Mynderse L, Patel K, Grudem M, Bakkum-Gamez J, Longenbach S, Block MS, Pitot HC, Garovic V, Weroha SJ, Jatoi A.

Psychooncology. 2016 May;25(5):605-9. doi: 10.1002/pon.3889. Epub 2015 Jun 22. No abstract available.

PMID:
26101949
31.

Dental Extractions and Preservation of Space for Implant Placement in Molar Sites.

Block MS.

Oral Maxillofac Surg Clin North Am. 2015 Aug;27(3):353-62. doi: 10.1016/j.coms.2015.04.001. Epub 2015 Jun 13. Review.

PMID:
26078092
32.

Second-line dovitinib in metastatic endometrial cancer.

Block MS, Dowdy SC.

Lancet Oncol. 2015 Jun;16(6):604-6. doi: 10.1016/S1470-2045(15)70190-7. Epub 2015 May 13. No abstract available.

PMID:
25981815
33.

Full-Arch Rehabilitation of a Patient With Cyclic Neutropenia.

Block MS, Brindis M, Block CA, Berron JM.

J Oral Maxillofac Surg. 2015 Sep;73(9):1734.e1-10. doi: 10.1016/j.joms.2015.03.073. Epub 2015 Apr 11.

PMID:
25913513
34.

Assessment of Bone Width for Implants in the Posterior Mandible.

Block MS, Scoggin ZD, Yu Q.

J Oral Maxillofac Surg. 2015 Sep;73(9):1715-22. doi: 10.1016/j.joms.2015.03.036. Epub 2015 Mar 21.

PMID:
25889373
35.

PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.

Winterhoff B, Freyer L, Hammond E, Giri S, Mondal S, Roy D, Teoman A, Mullany SA, Hoffmann R, von Bismarck A, Chien J, Block MS, Millward M, Bampton D, Dredge K, Shridhar V.

Eur J Cancer. 2015 May;51(7):879-892. doi: 10.1016/j.ejca.2015.02.007. Epub 2015 Mar 5.

36.

Plasma immune analytes in patients with epithelial ovarian cancer.

Block MS, Maurer MJ, Goergen K, Kalli KR, Erskine CL, Behrens MD, Oberg AL, Knutson KL.

Cytokine. 2015 May;73(1):108-13. doi: 10.1016/j.cyto.2015.01.035. Epub 2015 Mar 3.

37.

Maxillary fixed prosthesis design based on the preoperative physical examination.

Block MS.

J Oral Maxillofac Surg. 2015 May;73(5):851-60. doi: 10.1016/j.joms.2014.12.027. Epub 2015 Jan 8.

PMID:
25659360
38.

Sinus augmentation at the time of molar tooth removal: modification of Jensen technique.

Block MS.

J Oral Maxillofac Surg. 2015 Jun;73(6):1078-83. doi: 10.1016/j.joms.2014.12.037. Epub 2015 Jan 12.

PMID:
25659359
39.

A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients.

Jatoi A, Radecki Breitkopf C, Foster NR, Block MS, Grudem M, Wahner Hendrickson A, Carlson RE, Barrette B, Karlin N, Fields AP.

Oncology. 2015;88(4):208-13. doi: 10.1159/000369257. Epub 2014 Dec 6.

40.

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC.

Cancer Res. 2015 Jan 1;75(1):22-30. doi: 10.1158/0008-5472.CAN-14-2533. Epub 2014 Nov 14.

41.

Prevalence of sinus membrane thickening and association with unhealthy teeth: a retrospective review of 831 consecutive patients with 1,662 cone-beam scans.

Block MS, Dastoury K.

J Oral Maxillofac Surg. 2014 Dec;72(12):2454-60. doi: 10.1016/j.joms.2014.06.442. Epub 2014 Jun 27. Review.

PMID:
25236817
42.

Letter to the Editor Re: Kim, Nowzari, and Rich (2013).

Block MS, Clem D, Jensen OT, Le B, Lozada J, Moy PK, Norton MR, Testori T, Valentini P, Wallace SS, Zadeh HH.

Clin Implant Dent Relat Res. 2016 Feb;18(1):5-7. doi: 10.1111/cid.12241. Epub 2014 Sep 2. No abstract available.

PMID:
25181486
43.

Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.

Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, Cunningham JM, Rider DN, Preston C, Hartmann LC, Lawrenson K, Wang C, Tyrer J, Song H, deFazio A, Johnatty SE, Doherty JA, Phelan CM, Sellers TA, Ramirez SM, Vitonis AF, Terry KL, Van Den Berg D, Pike MC, Wu AH, Berchuck A, Gentry-Maharaj A, Ramus SJ, Diergaarde B, Shen H, Jensen A, Menkiszak J, Cybulski C, Lubiłski J, Ziogas A, Rothstein JH, McGuire V, Sieh W, Lester J, Walsh C, Vergote I, Lambrechts S, Despierre E, Garcia-Closas M, Yang H, Brinton LA, Spiewankiewicz B, Rzepecka IK, Dansonka-Mieszkowska A, Seibold P, Rudolph A, Paddock LE, Orlow I, Lundvall L, Olson SH, Hogdall CK, Schwaab I, du Bois A, Harter P, Flanagan JM, Brown R, Paul J, Ekici AB, Beckmann MW, Hein A, Eccles D, Lurie G, Hays LE, Bean YT, Pejovic T, Goodman MT, Campbell I, Fasching PA, Konecny G, Kaye SB, Heitz F, Hogdall E, Bandera EV, Chang-Claude J, Kupryjanczyk J, Wentzensen N, Lambrechts D, Karlan BY, Whittemore AS, Culver HA, Gronwald J, Levine DA, Kjaer SK, Menon U, Schildkraut JM, Pearce CL, Cramer DW, Rossing MA, Chenevix-Trench G; AOCS group; ACS, Pharoah PD, Gayther SA, Ness RB, Odunsi K, Sucheston LE, Knutson KL, Goode EL.

Cancer Immunol Res. 2014 Apr;2(4):332-40. doi: 10.1158/2326-6066.CIR-13-0136. Epub 2014 Jan 27.

44.

Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.

Block MS, Charbonneau B, Vierkant RA, Fogarty Z, Bamlet WR, Pharoah PD; Georgia Chenevix-Trench; for AOCS; /ACS Group, Rossing MA, Cramer D, Pearce CL, Schildkraut J, Menon U, Kjaer SK, Levine DA, Gronwald J, Culver HA, Whittemore AS, Karlan BY, Lambrechts D, Wentzensen N, Kupryjanczyk J, Chang-Claude J, Bandera EV, Hogdall E, Heitz F, Kaye SB, Fasching PA, Campbell I, Goodman MT, Pejovic T, Bean YT, Hays LE, Lurie G, Eccles D, Hein A, Beckmann MW, Ekici AB, Paul J, Brown R, Flanagan JM, Harter P, du Bois A, Schwaab I, Hogdall CK, Lundvall L, Olson SH, Orlow I, Paddock LE, Rudolph A, Eilber U, Dansonka-Mieszkowska A, Rzepecka IK, Ziolkowska-Seta I, Brinton LA, Yang H, Garcia-Closas M, Despierre E, Lambrechts S, Vergote I, Walsh CS, Lester J, Sieh W, McGuire V, Rothstein JH, Ziogas A, Lubiński J, Cybulski C, Menkiszak J, Jensen A, Gayther SA, Ramus SJ, Gentry-Maharaj A, Berchuck A, Wu AH, Pike MC, Van Den Berg D, Terry KL, Vitonis AF, Ramirez SM, Rider DN, Knutson KL, Sellers TA, Phelan CM, Doherty JA, Johnatty SE, deFazio A, Song H, Tyrer J, Kalli KR, Fridley BL, Cunningham JM, Goode EL.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1421-7. doi: 10.1158/1055-9965.EPI-13-0962. Epub 2014 Apr 16.

45.

Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer.

Wang C, Cicek MS, Charbonneau B, Kalli KR, Armasu SM, Larson MC, Konecny GE, Winterhoff B, Fan JB, Bibikova M, Chien J, Shridhar V, Block MS, Hartmann LC, Visscher DW, Cunningham JM, Knutson KL, Fridley BL, Goode EL.

Cancer Res. 2014 Jun 1;74(11):3084-91. doi: 10.1158/0008-5472.CAN-13-3198. Epub 2014 Apr 11.

46.

Use of sintered xenograft over allograft for ridge augmentation: technique note.

Block MS, Kaleem A.

J Oral Maxillofac Surg. 2014 Mar;72(3):496-502. doi: 10.1016/j.joms.2013.11.002. Epub 2013 Nov 16.

PMID:
24388178
47.

Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.

Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeney LA, Baglietto L, Giles GG, Severi G, Trabert B, Wentzensen N, Chenevix-Trench G; for AOCS/ACS group, Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlow I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, Lu K, Butzow R, Dörk T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles D, Paul J, Wu AH, Gayther SA, Hogdall E, Heitz F, Kaye SB, Karlan BY, Anton-Culver H, Gronwald J, Hogdall CK, Lambrechts D, Fasching PA, Menon U, Schildkraut J, Pearce CL, Levine DA, Kjaer SK, Cramer D, Flanagan JM, Phelan CM, Brown R, Massuger LF, Song H, Doherty JA, Krakstad C, Liang D, Odunsi K, Berchuck A, Jensen A, Lubinski J, Nevanlinna H, Bean YT, Lurie G, Ziogas A, Walsh C, Despierre E, Brinton L, Hein A, Rudolph A, Dansonka-Mieszkowska A, Olson SH, Harter P, Tyrer J, Vitonis AF, Brooks-Wilson A, Aben KK, Pike MC, Ramus SJ, Wik E, Cybulski C, Lin J, Sucheston L, Edwards R, McGuire V, Lester J, du Bois A, Lundvall L, Wang-Gohrke S, Szafron LM, Lambrechts S, Yang H, Beckmann MW, Pelttari LM, Van Altena AM, van den Berg D, Halle MK, Gentry-Maharaj A, Schwaab I, Chandran U, Menkiszak J, Ekici AB, Wilkens LR, Leminen A, Modugno F, Friel G, Rothstein JH, Vergote I, Garcia-Closas M, Hildebrandt MA, Sobiczewski P, Kelemen LE, Pharoah PD, Moysich K, Knutson KL, Cunningham JM, Fridley BL, Goode EL.

Cancer Res. 2014 Feb 1;74(3):852-61. doi: 10.1158/0008-5472.CAN-13-1051. Epub 2013 Nov 22.

48.

Fate of CPN-1 fixed points with q monopoles.

Block MS, Melko RG, Kaul RK.

Phys Rev Lett. 2013 Sep 27;111(13):137202. Epub 2013 Sep 26.

PMID:
24116811
49.

Horizontal posterior ridge augmentation: the use of a collagen membrane over a bovine particulate graft: technique note.

Block MS, Kelley B.

J Oral Maxillofac Surg. 2013 Sep;71(9):1513-9. doi: 10.1016/j.joms.2013.05.015.

PMID:
23948364
50.

Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer.

Carlson AM, Maurer MJ, Goergen KM, Kalli KR, Erskine CL, Behrens MD, Knutson KL, Block MS.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1730-5. doi: 10.1158/1055-9965.EPI-12-1368. Epub 2013 Jul 22.

Supplemental Content

Loading ...
Support Center